Clinical Evidence: Red Light Therapy for Pain Relief - What 565 Patients Revealed

Peer-reviewed research, including a publication in The Lancet, has examined photobiomodulation for pain relief - and three landmark systematic reviews together cover over 1,400 patients. This article walks through what each study actually found, what the data means, and what the limitations are.

We want to be clear upfront: one of those three studies was not published in The Lancet. An earlier version of this article incorrectly attributed the Bjordal 2003 review to The Lancet. It was published in the Australian Journal of Physiotherapy. We have corrected that error here. Accuracy matters, especially when citing clinical evidence.

Study 1: Bjordal and colleagues (2003) - Australian Journal of Physiotherapy

Full citation: Bjordal JM, Couppe C, Chow RT, Tuner J, Ljunggren EA. A systematic review of low level laser therapy with location-specific doses for pain from chronic joint disorders. Australian Journal of Physiotherapy. 2003;

Important note: This study was published in the Australian Journal of Physiotherapy, not in The Lancet. We are flagging this explicitly because this citation is sometimes misattributed online.

What the researchers did

Bjordal and colleagues conducted a systematic review and meta-analysis of randomised controlled trials examining low-level laser therapy (LLLT) for chronic joint pain. They focused specifically on trials using location-specific doses - meaning the treatment parameters were matched to the target tissue depth and anatomy rather than applied uniformly.

The review identified 11 high-quality RCTs meeting their inclusion criteria, covering a total of 565 patients.

What the data showed

The primary outcome was pain measured on a 100mm Visual Analogue Scale (VAS), where 0 represents no pain and 100 represents the worst imaginable pain. Across the 11 trials, active LLLT produced a mean weighted pain reduction of 29.8mm on the VAS compared to placebo (95% confidence interval: 18.9mm to 40.7mm).

A reduction of 29.8mm on a 100mm scale is considered clinically meaningful. The confidence interval is relatively tight and does not cross zero, which is important - it means we can be reasonably confident this difference is real and not a product of chance.

The review also found that patients receiving active treatment were approximately half as likely to report poor global health outcomes compared to those receiving placebo, with a relative risk of 0.52.

The location-specific dose point

One of the more practically significant findings from Bjordal 2003 is that trials using location-specific dosing - accounting for tissue depth and anatomy - produced better results than trials applying standard flat doses. This has informed how practitioners think about treatment protocols, particularly for deeper joints like the knee or hip versus more superficial tendons.

Study 2: Chow and colleagues (2009) - The Lancet

Full citation: Chow RT, Johnson MI, Lopes-Martins RA, Bjordal JM. Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials. The Lancet. 2009;

This study is genuinely published in The Lancet. It is a systematic review and meta-analysis of 16 RCTs examining LLLT specifically for neck pain.

What the researchers did

Chow and colleagues searched multiple databases and identified 16 randomised controlled trials meeting their quality thresholds. The trials covered a total of 820 patients and used wavelengths ranging from 632.6nm to 904nm. Some trials used visible red wavelengths, others near-infrared - a range relevant to most current clinical and consumer devices.

What the data showed

For chronic neck pain, active LLLT was associated with a relative risk of 4.05 for pain improvement compared to placebo (95% CI: 2.74-5.98). In plain terms: patients receiving active treatment were four times more likely to report meaningful improvement than those receiving a sham treatment.

On the VAS, pain intensity was reduced by 19.86mm compared to placebo for chronic neck pain. Critically, the benefit was not short-lived. Medium-term follow-up data showed a sustained pain reduction of 22.07mm on the VAS - the effect held or slightly increased at follow-up rather than fading.

For acute neck pain, the picture was more modest and results were less consistent across trials.

Why the distinction between acute and chronic matters

The Chow review found stronger effects in chronic presentations than acute ones. Chronic neck pain involves different underlying mechanisms - sensitisation, structural changes, persistent inflammation - and photobiomodulation's proposed mechanisms (modulating mitochondrial activity, reducing inflammatory cytokines, influencing neural sensitisation) may be better matched to these chronic processes.

Study 3: Tumilty and colleagues (2010) - Photomedicine and Laser Surgery

Full citation: Tumilty S, Munn J, McDonough S, Hurley DA, Basford JR, Baxter GD. Low level laser treatment of tendinopathy: a systematic review with meta-analysis. Photomedicine and Laser Surgery. 2010;

What the researchers did

Tumilty and colleagues reviewed 25 controlled trials examining LLLT for tendinopathy - conditions like tennis elbow (lateral epicondylitis), Achilles tendinopathy, and rotator cuff disorders. Tendinopathies are among the most common musculoskeletal complaints and often resistant to standard conservative treatment, making this a clinically relevant population.

Mixed results - and why that matters

The Tumilty review found mixed results. 12 of the 25 trials showed positive effects for LLLT. The other 13 did not reach significance. We want to be direct about this: a 48% positive rate in a systematic review is not a clean endorsement. It suggests the therapy works under some conditions and not others.

The meta-analysis helped identify what distinguished the positive trials:

• Wavelengths of 660nm, 830nm, and 904nm featured most consistently in positive studies
• Trials following dosage recommendations from the World Association for Laser Therapy (WALT) performed better than those using non-recommended doses
• Application method and tissue contact quality appeared to influence outcomes

Where the data was clearest

For tennis elbow (lateral epicondylitis), grip strength improved by 9.59kg compared to placebo (95% CI: 5.90kg to 13.27kg). For Achilles tendinopathy, pain on the VAS was reduced by 13.64mm compared to sham treatment.

For wrist and forearm tendinopathy - where the joint is relatively superficial and easy to target precisely - a device like the Lumovex Wrist Strap delivers both 660nm and 850nm wavelengths directly to the affected area without the need to hold a device in place.

These are specific, measurable outcomes with confidence intervals that do not include zero - the effect is real in these subgroups, even if the broader tendinopathy picture is less definitive.

What these three studies tell us collectively

Taken together, Bjordal 2003, Chow 2009, and Tumilty 2010 cover over 1,400 patients across dozens of randomised controlled trials. The common threads are:

• Consistent effects for chronic rather than acute pain presentations
• Stronger results when dosage parameters follow evidence-based guidelines
• Wavelengths in the 630-904nm range feature across positive trials
• Pain reductions are statistically significant and generally exceed thresholds for clinical meaningfulness
• Not every trial shows positive results - outcomes depend on protocol, indication, and application

This is the honest picture: photobiomodulation has a meaningful body of clinical evidence for specific pain applications. It is not a universal solution for all pain, and trial quality and dosing matter considerably.

For joint and lower back discomfort, the Lumovex Belt provides hands-free targeted treatment at both 660nm and 850nm wavelengths. For larger treatment areas such as the back or shoulders, the Lumovex Pro Panel 540 delivers both wavelengths across a wider coverage area.

Important disclaimer

This article is for educational purposes only. The studies described here were conducted under controlled clinical conditions with medical-grade equipment and supervised protocols. Red light therapy devices are not medical treatments and are not intended to diagnose, treat, cure, or prevent any disease or medical condition. If you have chronic pain, tendinopathy, or any musculoskeletal condition, consult a qualified healthcare professional before starting any new therapy.

Citations to clinical research are provided for transparency and educational context. Referencing a study does not imply that a consumer device replicates clinical trial conditions.